• QureBio

  Participated · Series B · Dec 2021

  QureBio develops bispecific and multispecific antibody and protein therapeutics using proprietary platforms including I2T and T‑cell and NK‑cell engager platforms. Its pipeline includes Q‑1802 (Claudin18.2/PD‑L1 bispecific) with Phase II enrollment nearly complete and preparations for Phase III in China, Q‑1801 (SIRPα/PD‑L1 bispecific) poised to begin clinical studies, and a PD‑1 antibody‑cytokine fusion candidate. The company has regulatory clearances to initiate clinical trials in both China and the United States for multiple candidates. QureBio was founded in 2017 and is based in Shanghai. It has established collaborations with BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific to co‑develop therapies. The recent financing will be used to accelerate clinical trials and advance its core pipeline globally. QureBio is dedicated to the development of innovative antibody drugs. The company is invested in and incubated by Viva BioInnovator. In December 2021 QureBio announced it had completed nearly 200 Million RMB in a Series B financing. The Series B round was led by BOCOM International Holdings. Other participants in the round included Guoshun Investment, Oriza Holdings, Lihe Hongxin Venture Investment, Tianfu Sanjiang Capital, Spinnotec and Longmen Capital.

• WeMed

  Participated · Series D · Apr 2021

  Weimai Medical, founded in 2014, is a national high‑tech enterprise specializing in interventional imaging full‑process management and an integrated “eye‑hand‑brain” solution. Its product lines include high‑end flat‑panel DSA (Aurora), mobile and surgical C‑arms (mid C and small C), and interventional surgical robots, with technical synergies across lines. The company completed overseas M&A and has an international R&D, manufacturing and sales strategy; its Aurora DSA received NMPA and CE dual certification in 2020 and is used in multiple hospitals and exported to 20+ countries. In 2016 Weimai acquired the EC mid‑C brand, and its mid‑C product has CE and NMPA certifications and broad clinical adoption. The company’s self‑developed interventional surgical robot has completed animal experiments and is positioned to accelerate clinical progress and integration with DSA systems. The recent financing will be applied to brand promotion, domestic and overseas commercialization of certified C‑series products, and to speed clinical rollout of the surgical robot as part of its plan to complete an end‑to‑end interventional treatment management offering. Founded in 2014, Weimai Medical focuses on R&D and production of interventional diagnostic imaging equipment and related robotics. Its product lineup includes ground‑mounted intelligent flat‑panel DSA (极光), mobile and surgical C‑arms (large C, mid‑C, small C) and a remote‑operable interventional robot. 极光 DSA received CE certification in early 2020 and recently obtained NMPA approval; the company’s mid‑C product (acquired from Italy’s EC) also holds NMPA registration and has been sold internationally. Weimai reports installations of its DSA in multiple leading hospitals (including Beijing Tiantan Hospital, First Affiliated Hospital of Zhengzhou University, Zhengzhou Central Hospital and Hebei University Affiliated Hospital) and has overseas sales in 20+ countries for the acquired mid‑C product. The company positions its small‑C Elfinbot100 as a domestically high‑end alternative to imported orthopedics C‑arms. Management says the C+ proceeds will be used for brand building, product promotion and development of segmented models. Weimai highlights policy and market tailwinds for domestic large medical equipment and aims to accelerate domestic and international commercial expansion. Weimai Medical (founded 2014, Beijing) focuses on R&D, manufacturing and commercialization of interventional diagnostic and treatment equipment, with product lines that include large vascular DSA systems, mobile angiography (mid C), surgical C‑arms (small C) and interventional robots. The company reports more than 30 granted patents covering core technologies such as digital subtraction imaging and has pursued overseas M&A to build an international R&D, manufacturing and sales footprint. Weimai says its seven‑axis flat‑panel DSA delivers performance comparable to mid‑to‑high‑end international products while costing significantly less, aiming to enable domestic import substitution. Its devices are in trial or use at multiple top-tier Chinese hospitals and the company has completed clinical trials for its high‑end large C product with pending registration approval. Management plans to continue software and hardware upgrades across product lines and is investing heavily in interventional robot development and deeper integration of imaging and robotic solutions under 5G capabilities. The company recently completed a new financing round to support clinical promotion of certified products and to accelerate R&D of robotic systems.

• SinoTau

  Participated · Series D · Feb 2021

  先通医药 is an innovative biopharma company focused on discovery, development, production and clinical promotion of radiopharmaceuticals and related monoclonal-antibody conjugates. Its pipeline targets oncology, neurodegenerative and cardiovascular indications via both diagnostic and therapeutic radioactive drugs. The company reports four diagnostic candidates and two therapeutic candidates have entered clinical trials. In 2020 it completed a RMB 280 million C round with strategic investors including Tongfu Innovation Industrial Investment Fund and Sinopharm Capital. Recently it closed a RMB 320 million D round and, together with prior closings, has raised RMB 600 million within six months. Proceeds from the D round will fund preclinical development and clinical studies of its diagnostic and therapeutic radiopharmaceutical projects. The company says it aims to integrate upstream and downstream industry resources to accelerate domestic and global radiopharmaceutical development.

• Sirnaomics

  Participated · Series D · Oct 2020

  Sirnaomics is a biopharmaceutical company developing RNAi therapeutics, with a portfolio targeting oncology, anti‑fibrotic, anti‑viral and metabolic disorders. Its lead product candidates include STP705 and STP707, dual‑targeting siRNA therapeutics against TGF‑β1 and COX‑2 for local or systemic administration. The company is advancing systemic RNAi delivery platforms including siRNA‑chemodrug conjugates and proprietary GalNAc‑siRNA conjugates, and plans clinical evaluation in immune‑oncology combinations with PD‑1/PD‑L1 inhibitors. Proceeds from the announced Series E financing will fund continued development across its pipeline, advance delivery technologies, and strengthen large‑scale manufacturing capacity. Sirnaomics operates as a Delaware corporation headquartered in Gaithersburg, Maryland, with subsidiaries in Suzhou and Guangzhou, China. Sirnaomics Inc., based in Gaithersburg, Maryland, discovers and develops RNAi therapeutics. Led by Patrick Lu, PhD, Founder, President and CEO, the company focuses on oncology, anti‑fibrotic therapeutics and viral infection and has subsidiaries in Suzhou and Guangzhou, China. Its lead candidates, STP705 and STP707, are dual‑targeting siRNA therapeutics against TGF‑β1 and COX‑2 for local and systemic administrations to treat various cancers and fibrotic diseases. The company reported positive results from a Phase IIa study for treatment of Cutaneous Squamous Cell Carcinoma in‑situ and plans multiple clinical studies to further evaluate these candidates. A clinical focus will be immune‑oncological evaluation of the dual‑targeted siRNA inhibitors based on potential synergistic effects with immune checkpoint inhibitors observed in preclinical and clinical settings. Sirnaomics raised $105M in a Series D financing to fund continued development of its RNAi therapeutics across indications including cancers, fibrosis, metabolic diseases and viral infections. Sirnaomics discovers and develops RNAi therapeutics targeting cancer and fibrotic diseases. Its lead candidate, STP705, leverages a dual-targeting approach and was in a Phase II study for non-melanoma skin cancer at the time of the report. The company planned a second clinical trial for cholangiocarcinoma and hepatocellular carcinoma expected to begin in the second half of 2019. Sirnaomics said it would use proceeds from its recent financing to support its clinical programs and to advance its technology platforms. The company is led by Patrick Lu, PhD, and maintains subsidiaries in Suzhou and Guangzhou. No operating metrics were reported in the article. Sirnaomics develops RNAi therapeutics using pluripotent siRNA cocktail design and nanoparticle-enhanced delivery. The company’s lead candidate, STP705, targets TGF-β1 and COX-2 and has shown anti-fibrotic and anti-tumor activity in preclinical models. STP705 has a fully developed, validated manufacturing process and a preclinical safety profile that supports human clinical studies. STP705 is in a Phase IIa clinical study for hypertrophic scar in the U.S., and the same indication has been approved for clinical study by the Chinese FDA. The company said proceeds will expand clinical programs for its anti-fibrosis and anti-cancer RNAi therapeutics, strengthen management, and bolster pre-clinical development of new drug candidates. Sirnaomics is a Delaware corporation headquartered in Gaithersburg, Maryland, with subsidiaries in Suzhou and Guangzhou, China, and is led by Founder and CEO Dr. Patrick Y. Lu and CMO Dr. Michael Molyneaux. Sirnaomics is a Gaithersburg, Maryland–based biopharmaceutical company focused on the discovery and development of RNAi therapeutics. The company has developed a portfolio of intellectual property in areas including anti-fibrotic medicine and cancer therapeutics. Its lead product candidate, STP705, is an anti-fibrosis siRNA therapeutic that uses a dual-targeted inhibitory approach and PNP-enhanced delivery. STP705 has shown activity in animal models ranging from skin hypertrophic scar to liver and lung fibrosis. Sirnaomics intends to use new funding to advance its anti-fibrosis programs into clinical development and expected to enter a Phase I trial with STP705 in the early second half of 2016. The company also operates subsidiaries in Suzhou and Guangzhou, China.

• KYEE

  Participated · Series D · Sep 2020

  Shanghai Kyee Technology is a China-based healthtech startup that integrates cloud computing and software-as-a-service to deliver smart healthcare solutions. The company says it has served over 13,000 medical institutions in China. Founded in 2014, Shanghai Kyee focuses on applying modern technologies to healthcare customers and institutions. The article highlights the company’s recent fundraising activity, indicating investor confidence in its product offering and market penetration. No revenue figures were disclosed in the article. The company’s technology emphasis and institutional customer base position it as a scale-stage healthtech provider within China.

No current team members are available.